Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mitiglinide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 7/20 | 0.51 |
| ▸ | CPA3 | P15088 | 3/20 | 0.51 |
| ▸ | CPB1 | P15086 | 1/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitiglinide SCHEMBL305840 | 1.00 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL6496289 | 1.00 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL1219700 | 0.99 | CPA1 (0.50) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL199175 | 0.99 | CPA1 (0.50) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL4457950 | 0.99 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL49085 | 0.99 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL876930 | 0.99 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL4457953 | 0.99 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL9049521 | 0.99 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL2864873 | 0.99 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960349-B2 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | claimed |
| EP-1773877-B1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | claimed |
| EP-2021354-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | Brystol-Myers Squibb Company (US) | 2009-02-11 | — | — | EP | claimed |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-10-02 | — | — | US | claimed |
| US-7417028-B2 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | claimed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | claimed |
| EP-1883652-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2008-02-06 | — | — | EP | claimed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | claimed |
| WO-2007140284-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | claimed |
| US-7238670-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | claimed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | claimed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | claimed |
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | GLP1R, GIPR, IAPP | CPA1 848/4885CPA3 1433/4885CPB1 746/4885 |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | CPA1 146/4885CPA3 579/4885CPB1 227/4885 |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, GIPR, IAPP | CPA1 280/4885CPA3 872/4885CPB1 404/4885 |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, IAPP | CPA1 822/4885CPA3 1509/4885CPB1 690/4885 |
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | CPA1 1748/4885CPA3 1840/4885CPB1 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.